

Common Drug Review 1

Submission Status

Product:	Stelara
Generic Name:	ustekinumab
·	
Manufacturer:	Janssen Inc.
Indication:	Arthritis, Psoriatic

Submission Type: Pre-NOC - Initial

Date Submission Received: 2013-Oct-30 Date NOC Issued: 2014-Jan-21

Orginal Targeted CDEC Meeting: 2014-Mar-19 Priority Review Granted: Not Requested

Priority Review Granted: Not Requested **Target Target Actual** Comments **Phase Time** Date 2 **CDR Date** (Business Days) Submission placed in queue in accordance with CDR procedures. Review to be initiated pending availability of resources and target dates Submission deemed complete 5 2013-Nov-06 2013-Nov-06 will be undated Review has been initiated 2014-Apr-01 Patient Input invitations will be posted at a later date (please refer to CDR Update 95) Patient group input submission received 3 2014-Apr-01 2014-Apr-01 Call for patient input posted on 2014-Feb-10 Patient group input deadline: 2014-Apr-01 Patient input summary sent for review on 2014-Apr-14 Patient group input summary comments received 5 2014-Apr-23 2014-Apr-23 Patient input summary feedback deadline: 2014-Apr-23 Patient input summary feedback received New target date: 2014-Jun-16 CDR review reports sent to manufacturer4 45 2014-Jan-28 2014-Jun-19 New target date: 2014-Jun-19 Comments from manufacturer on CDR review reports received New target date: 2014-Jun-25 7 2014-Feb-06 2014-Jun-30 by CADTH New target date: 2014-Jun-30 Redaction response from manufacturer on CDR review reports New target date: 2014-Jun-30 3 2014-Feb-11 2014-Jul-04 received by CADTH New target date: 2014-Jul-04 CDEC meeting New target date: 2014-Sep-17 2014-Mar-19 2014-Sep-17 CDEC recommendation & redacted CDR review reports New target date: 2014-Sep-24 5 to 7 2014-Mar-26 2014-Sep-26 sent to drug plans and manufacturer New target date: 2014-Sep-26 Embargo period and validation of redacted CDR review reports New target date: 2014-Oct-08 10 Manufacturers may make a request for reconsideration and 2014-Apr-09 2014-Oct-10 New target date: 2014-Oct-10 drug plans may make a request for clarification of the recommendation Final recommendation sent to drug plans and manufacturer (No requests for clarification are made AND no request for New target date: 2014-Oct-20 5 2014-Apr-16 2014-Oct-20 reconsideration is made or request for reconsideration is Notice of final recommendation issued esolved) 2014-Oct-22 2014-Oct-22 CDEC final recommendation posted 6 variable

Final CDR review reports and patient input posted 7

2016-Nov-24

2016-Nov-24

variable

This CDR Project Status Report is posted every other week, reflecting status as of the end of day Wednesday (4:00 pm ET) of that week.

2016-Dec-09 SR0359-000

¹ Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

² The target dates for this report are based on the CDEC meeting schedule, which is posted on www.cadth.ca.

³ The deadline for patient group input is 15 business days after CADTH receives the submission or up to 35 business days if advance notice (20 business days maximum) of a submission is received from the manufacturer.

⁴ Target time is calculated, based on the date the reviewers receive copies of the manufacturer's submission. Target time does not include the time allocated for receipt of manufacturer's additional electronic copies (5 business days) and time allocated for distribution of electronic copies to reviewers (3 business days).

⁵The Recommendation is held in confidence by all stakeholders and not acted upon until after CADTH has issued the notice of Final Recommendation.

⁶ The target date for posting the CDEC final recommendation depends on several factors including the need for consultation with the manufacturer regarding redaction issues.

⁷ The timing of the posting of CDR review reports depends on several factors, including the need for consultation with the manufacturer in case of disagreement with regard to redactions made.